Company on track to initiate OCU410 Phase 3 trial for geographic atrophy this quarter
Top-line results for OCU400 and OCU410ST expected in 1Q and 2Q 2027, respectively
Company targets BLA and MAA filings for OCU410 in 2028
Overview
US gene therapy firm's Q2 revenue rose and beat analyst expectations
Net loss per share widened to $0.07 from $0.05 yr/yr
Company closed $130 mln convertible notes financing, extending cash runway into 2028
Result Drivers
HIGHER R&D SPENDING - Increased research and development expenses as late-stage clinical programs advanced
PIPELINE PROGRESS - Advanced clinical programs, including FDA clearance for OCU410 Phase 3 trial and completion of OCU400 PPQ batches
FINANCING ACTIVITIES - Closed $130 mln convertible notes financing, retired higher-interest debt, and extended cash runway into 2028
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
OCGN•
